Bilastine Form I vs Form II: What’s the Difference?
Bilastine Form I vs Form II: Understanding Polymorphic Differences
Introduction
In pharmaceutical ingredient manufacturing, even minor molecular variations can significantly impact drug performance, stability, and regulatory approval. Bilastine polymorphism exemplifies this-two crystalline forms of the same antihistamine can behave differently in formulation, processing, and shelf-life management.
This guide explores the practical and regulatory implications of Bilastine Form I and Form II, helping pharmaceutical buyers, formulators, and researchers make informed sourcing decisions. As a WHO-GMP certified API manufacturer with over 80 years of pharmaceutical heritage, BioSynth offers expertise and reliable supply in polymorph control.
Key Scientific References
This article draws on industry-standard guidance and pharmacopeial monographs:
- European Medicines Agency (EMA): Bilastine Assessment Reports
- ICH Q6A: Specifications: Test Procedures and Acceptance Criteria
- FDA Guidance: Nonsterile Semisolid Dosage Forms-Scale-Up and Postapproval Changes
- USP <914>: Polymorph Characterization and Stability Testing
What Is Bilastine API?
Bilastine API is a selective second-generation H1-receptor antagonist used for symptomatic relief of allergic rhinitis and chronic urticaria. Unlike first-generation antihistamines, bilastine offers:
- High H1-receptor selectivity with minimal off-target effects
- Long half-life (~14.5 hours) permitting once-daily dosing
- Minimal sedation due to poor blood-brain barrier penetration
- Favorable safety profile with minimal hepatic metabolism
- Fast onset of action (relief within 20-30 minutes)
Understanding Polymorphism in Crystalline APIs
Polymorphism refers to the ability of a chemical compound to exist in multiple distinct crystalline forms. While chemically identical, polymorphs differ in their physical and thermal properties:
- Crystal lattice arrangement and internal structure
- Melting point and thermal stability
- Solubility and dissolution rate in aqueous media
- Bulk density, particle size, and flow properties
- Chemical stability and susceptibility to degradation
- Bioavailability in pharmaceutical formulations
These differences are not merely academic-they directly influence manufacturing consistency, regulatory compliance, shelf-life stability, and therapeutic effectiveness.
Bilastine Form I vs Form II: Comparative Analysis
| Property | Form I (Orthorhombic) | Form II (Monoclinic) |
| Crystal Structure | Stable orthorhombic form | Metastable monoclinic form |
| Thermal Stability | Higher; resistant to conversion | Lower; may convert to Form I over time |
| Solubility Profile | Moderate and consistent | Higher but more variable |
| Regulatory Status | Widely accepted in DMFs | Under evaluation in some regions |
| Processing Behavior | Superior flow and compression | Slightly inferior handling |
Technical Differences & Implications
Form I (Orthorhombic): The Preferred Manufacturing Form
Form I is thermodynamically stable and remains the dominant polymorph under standard storage and processing conditions. Its superior thermal stability ensures predictable behavior during long-term storage, international transport, and scaled manufacturing. Form I exhibits reliable flow characteristics and compression behavior ideal for high-speed tableting operations, making it the industry standard for regulated markets.
Form II (Monoclinic): Higher Solubility, Lower Stability
Form II demonstrates higher aqueous solubility in some dissolution profiles, which may theoretically enhance bioavailability. However, this form is metastable and prone to conversion to Form I, especially under heat, humidity, or prolonged storage. While Form II may suit specific dissolution-driven formulation strategies, its instability introduces manufacturing and regulatory complexity.
Why Regulatory Bodies Care About Polymorphs
Regulatory agencies-including EMA, FDA, and PMDA-require consistent polymorphic declaration in Drug Master Files (DMFs) because polymorph differences can affect:
- Bioavailability and bioequivalence (changing form can affect plasma levels)
- Shelf-life stability (metastable forms may degrade faster)
- Manufacturing reproducibility (consistency impacts quality)
- Therapeutic outcomes (patient safety and efficacy)
Note: Acceptance of any polymorphic form depends on jurisdiction, dossier data quality, formulation composition, and the specific regulatory pathway (ANDA, NDA, MAA).
Bilastine API Sourcing: Key Evaluation Factors
1. Regulatory Documentation & Filing Status
Verify the manufacturer has filed or maintains approved DMFs, CEPs, or USDMF documentation for the specific polymorph. Check filing status with EMA, FDA, or Canadian regulatory bodies as applicable.
2. Formulation Compatibility Testing
Buyers manufacturing high-speed tablet lines should prioritize consistent flowability and compression behavior to reduce downtime and weight variation risk. Form I’s superior handling characteristics prove valuable in these scenarios.
3. Shelf-Life & Supply Chain Stability
A thermodynamically stable form ensures longer shelf life, reducing risks of recrystallization or form conversion during international transportation and storage-critical for global API sourcing.
4. Certificate of Analysis (COA) Verification
Ensure polymorph designation is explicitly stated and consistently recorded in each batch’s COA and quality documentation.
BioSynth: 80+ Years of Pharmaceutical Excellence
Established in 1943, BioSynth brings over 80 years of pharmaceutical manufacturing heritage to API development. Our Hyderabad facility serves over 20 export countries with a portfolio spanning antihistamines, antipsychotics, TB drugs, and cardiovascular APIs.
Quality Certifications & Compliance
- WHO-GMP (Good Manufacturing Practices) certification
- ISO 9001:2015 Quality Management System
- ICH Q7 GMP Declaration compliance
- CDSCO written confirmation certification for select products
- Rigorous adherence to pharmacopeial standards (USP, BP, Ph.Eur.)
Controlled Polymorphism & Solid-State Chemistry
BioSynth’s QC teams employ advanced analytical techniques to ensure polymorph consistency:
- X-Ray Powder Diffraction (XRPD): Confirms crystal structure identity and purity against approved reference standards.
- Differential Scanning Calorimetry (DSC): Measures thermal transitions and confirms thermal stability profiles.
- Thermogravimetric Analysis (TGA): Monitors degradation behavior and moisture content.
- Particle Size Distribution (PSD): Ensures consistent flow and compression properties.
Our QC teams routinely compare XRPD fingerprint patterns and DSC thermal transitions against approved internal reference standards before batch release, ensuring every shipment meets specifications.
Manufacturing & Supply Capabilities
- Bilastine Form I production with controlled crystallization parameters
- Current capacity: 2 MT/month with scalability
- Batch traceability and full documentation for regulatory filings
- Process development expertise in polymorph selectivity
- Stability data packages supporting long-term shelf-life claims
- Supply chain coordination managing moisture control and transit documentation
A Balanced Perspective on Form Selection
While Form I is preferred for stability and regulatory familiarity, Form II may offer specific advantages in dissolution-driven formulation strategies depending on dosage design. Neither form is universally superior-the optimal choice depends on your formulation’s stability targets, bioavailability goals, manufacturing capability, and regulatory strategy. The decision should be guided by comparative formulation studies and risk assessment rather than cost alone.
Selecting the Right Bilastine API Supplier
Buyers should prioritize suppliers based on consistency, responsiveness, audit readiness, documentation depth, and long-term reliability-not pricing alone when evaluating API manufacturers for regulated pharmaceutical sourcing. Key evaluation criteria include:
- Demonstrated GMP compliance and audit history
- Batch consistency and analytical testing transparency
- Regulatory dossier support (DMF, technical documentation)
- Supply reliability and inventory management
- Technical expertise and process development capability
- Communication responsiveness and customer support
Documentation & Supply Chain Transparency
BioSynth supports formulation companies, traders, and regulated-market buyers with comprehensive documentation, including:
- Certificates of Analysis (CoA) with polymorph designation
- Material Safety Data Sheets (MSDS)
- Stability summaries and long-term stability data
- Process overview and manufacturing details
- Impurity profiling and process-related substance analysis
- Regulatory dossiers subject to customer qualification
Our export coordination teams manage packaging integrity, moisture control, and transit documentation to reduce risk during international shipment, ensuring API quality from manufacturing through final delivery.
Frequently Asked Questions
What is the difference between Bilastine Form I and Form II?
They are polymorphs-different crystalline arrangements of the same chemical entity. Form I (orthorhombic) is thermodynamically stable, exhibits superior thermal stability, and features consistent flow properties. Form II (monoclinic) is metastable with higher solubility but lower stability. Form I is preferred in regulated markets due to its reliability and documented regulatory acceptance.
Is Bilastine Form I suitable for high-speed tableting?
Yes. BioSynth’s Form I demonstrates reliable flow and compressibility, making it ideal for direct compression and wet granulation methods used in high-speed tablet manufacturing.
Do regulatory authorities care about the specific polymorph?
Absolutely. Regulatory agencies expect consistent polymorph disclosure in Drug Master Files. Changes in polymorphic form can affect bioavailability, stability, and therapeutic outcomes. Polymorphic differences must be justified and documented in NDAs, ANDAs, or MAAs.
Which form is better-Form I or Form II?
Neither is universally superior. Form I is preferred for stability and regulatory familiarity, while Form II may offer advantages in specific dissolution-driven strategies. Selection depends on your formulation’s stability targets, bioavailability goals, regulatory pathway, and manufacturing capability. Conduct comparative formulation studies to guide your decision.
Can BioSynth supply regulatory documentation for Bilastine?
Yes. BioSynth provides complete regulatory support including stability studies, technical dossiers, process overviews, and DMF/CEP documentation on request. Our technical team works with your regulatory team to ensure seamless filing and approval.
What is the CAS Number for Bilastine API?
The CAS Number is 202189-78-4. This unique identifier ensures accurate identification across regulatory databases, manufacturing records, and scientific literature, maintaining consistency and traceability throughout the supply chain.
Can BioSynth provide batch traceability for Bilastine?
Yes. Qualified customers can request batch-linked manufacturing records and quality documentation based on commercial requirements, ensuring full transparency and regulatory compliance.
Partner with BioSynth for Reliable Bilastine Supply
The choice between Bilastine Form I and Form II is not merely a technical detail-it reflects your formulation strategy, regulatory approach, and commitment to patient safety. BioSynth’s decades of manufacturing expertise, WHO-GMP infrastructure, and proven track record position us as a reliable partner for Bilastine Form I API sourcing globally.
Contact BioSynth today for Form I samples, technical consultations, regulatory dossier support, or bulk quotes. Our team is ready to discuss your specific requirements and provide the high-quality, well-documented Bilastine API your formulation deserves.
BioSynth follows quality, safety, environmental, and documentation practices aligned with pharmaceutical manufacturing compliance frameworks, ensuring ethical and responsible sourcing relationships.
Post a comment